Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jul 15;38(9):1430-1431.
doi: 10.1097/QAD.0000000000003911. Epub 2024 Jun 27.

Should we continue to use tenofovir disoproxil fumarate/lamivudine/dolutegravir for treatment of pregnant women? Interpreting the PROMISE trial

Andrew M Hill  1 , Daniel Elbirt  2   3
Affiliations
Editorial

Should we continue to use tenofovir disoproxil fumarate/lamivudine/dolutegravir for treatment of pregnant women? Interpreting the PROMISE trial

Andrew M Hill et al. AIDS. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Clinton Health Access Initiative: 2023 HIV Market Report. The state of the HIV market in low- and middle-income countries. Available at: https://www.clintonhealthaccess.org/report/2023-hiv-market-report-the-st... . [Accessed 22 March 2024].
    1. WHO | Updated recommendations on first-line and second-line antiretroviral regimens and postexposure prophylaxis and recommendations on early infant diagnosis of HIV [Internet]. WHO. Available at: http://www.who.int/hiv/pub/guidelines/ARV2018update/en/ .[Accessed 22 March 2024]
    1. WHO. WHO recommends dolutegravir as preferred HIV treatment option in all populations. Available at: https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-... . [Accessed 22 March 2024]
    1. Dadabhai S, Chou VB, Pinilla M, Chinula L, Owor M, Violari A, et al. Effects of preterm birth, maternal ART and breastfeeding on 24-month infant HIV-free survival in a randomised trial . AIDS 2024; 38:1304–1314.
    1. Hill A, Khoo S, Back D, Pozniak A, Boffito M. Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors? . J Int AIDS Soc 2014; 17: (4 Suppl 3): 19583.

MeSH terms